

Psychiatry Drug Alerts 2018 Self-Assessment Module 5: Peer Comparison

You recently participated in an ABPN-approved Self-Assessment activity relevant to your specialty and/or subspecialty. This peer comparison report provides you with feedback on your performance, relative to your peers, on the test module. In order to recognize your current knowledge base and to identify specific topics where further study may be needed, please review your answers to the following questions and compare them with those of your peers.

1) Results of an observational study suggest that coadministration of quetiapine and venlafaxine could influence antidepressant action.

True	100.00 %
False	0.00 %

2) In this analysis, comedication was associated with a 29.3% increase in levels of O-desmethylvenlafaxine and a 15.8% increase in the active moiety, indicating _____ venlafaxine clearance.

Increased	0.00 %
Reduced	100.00 %

3) The FDA has issued a warning that lamotrigine can cause hemophagocytic lymphohistiocytosis (HLH), a rare but serious immune system reaction. HLH triggers an uncontrolled immune response that can lead to serious _____ issues.

Liver and kidney	0.00 %
Lung	0.00 %
Blood cell	0.00 %
All of the above	100.00 %

4) A review of published case reports suggests that rechallenge with clozapine may be an option for patients who have stabilized following drug-induced neutropenia or neuroleptic malignant syndrome. Rechallenge after _____ or myocarditis is not advised.

Stevens-Johnson Syndrome	0.00 %
Toxic epidermal necrolysis	0.00 %
Agranulocytosis	100.00 %
All of the above	0.00 %

5) There is existing concern that clozapine-associated cardiovascular effects may increase mortality risk. However, the results of a meta-analysis of studies lasting more than a year indicate that continuous use of clozapine appears to be associated with _____ compared with other antipsychotics.

Reduced cardiovascular effects	0.00 %
Reduced mortality	100.00 %
Improved metabolic profile	0.00 %
None of the above	0.00 %

6) Possible explanations for this result include superior efficacy, leading to improved function and self-care, and closer clinical:

Monitoring	0.00 %
Surveillance	0.00 %
Both of the above	100.00 %

7) In a manufacturer-sponsored trial, a combined formulation of aripiprazole and sertraline was superior to sertraline plus placebo in patients with resistant depression. Aripiprazole–sertraline was significantly superior to placebo–sertraline for:

Decrease in mean MADRS score	0.00 %
Response	0.00 %
Remission	0.00 %
All of the above	100.00 %

8) Akathisia occurred in 12.9% of the aripiprazole–sertraline group and 3.4% of the placebo–sertraline group. The low incidence of akathisia, relative to other trials, may be due to:

The relatively low aripiprazole dose	92.86 %
Slow titration	0.00 %
Older treatment group	0.00 %
All of the above	7.14 %

9) Mazindol is a _____ reuptake inhibitor hat was previously introduced for treatment of obesity but withdrawn from the market because of low sales.

Serotonin	0.00 %
Noradrenaline	0.00 %
Dopamine	0.00 %
All of the above	100.00 %

10) In a phase-II placebo-controlled trial, controlled-release mazindol was effective in adults with ADHD, with an effect size _____ stimulants.

Greater than	7.14 %
Comparable to	92.86 %
Lower than	0.00 %

11) The FDA recently approved lofexidine hydrochloride, the first nonopioid medication for the alleviation of opioid withdrawal symptoms in adults in order to expedite abrupt discontinuation. The newly approved drug _____ a treatment for opioid use disorder.

Is	7.14 %
Is not	92.86 %

12) In a large trial in a general population of smokers with or without established psychiatric disorders, smoking-cessation medications _____ associated with cardiovascular risk.

Were	0.00 %
Were not	100.00 %

13) Results of this analysis did not differ for the period during treatment, during the 30 days after completion, or at 1 year, nor did they differ in patients in _____ cardiovascular risk categories.

Low	0.00 %
Medium	0.00 %
High	0.00 %
Any of the above	100.00 %

14) Brexpiprazole and lurasidone are both believed to have neutral effects on weight, but there have been no head-to-head comparisons reported. In a network meta-analysis that compared placebo-controlled acute treatment trials in patients with schizophrenia, _____ was associated with somewhat less weight gain and better metabolic outcomes.

Brexpiprazole	7.14 %
Lurasidone	92.86 %